Brief: Synact Pharma Recieves Pre-IND Response From The U.S. FDA
29/06/2022 17:02
June 29 (Reuters) - SynAct Pharma AB SYNACT.TE :
* SYNACT PHARMA RECIEVES PRE-IND RESPONSE FROM THE US FDA
Source text for Eikon: ID:nWkr8Zf2Tk
Further company coverage: SYNACT.TE
((Reuters.briefs@thomsonreuters.com;))
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026